A phase II research study of arsenic trioxide (Trisenox) in patients with myelodysplastic syndromes (MDS)
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2012
At a glance
- Drugs Arsenic trioxide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 10 Oct 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 24 Dec 2005 New trial record.